Anti-viral developer Alios raises $8M more for $32M
Alios BioPharma, developer of anti-viral therapies, has tacked $8 million onto its first round of funding, bringing its total to $32 million. The new money came solely from SR One. Based in South San Francisco, the company plans to use the money to push its… Continue Reading
Cell Biosciences to launch new tech with $10M
Cell Biosciences announced that it’s just brought in $10 million in a third round of funding to launch its new protein analysis technology used to track cellular pathways. It plans to sell its products to labs and research institutions that are developing medications and chemical… Continue Reading
Life-science briefing: Tuesday, March 25, 2008
TODAY’S HEADLINES:
Antibody-discovery startup Adimab raises new funding (release)
Lung-device maker Spiration gets $19M (release)
Sample-prep startup Protein Discovery pulls in $10M (release)
Inogen takes in $13M for portable oxygen device (VentureWire)
Healthcare IT concern Medaptus raises $11M for expansion (VentureWire)
Contract lab Synexis raises $14M (peHUB)
Medical-device VC firm BioStar Ventures takes… Continue Reading
Life-science briefing: Thursday, March 20, 2008
TODAY’S HEADLINES:
Vantia Thera spins out of Ferring, raises £19M (PDF release)
Third Eye gets $150K for intracranial-pressure monitor (release)
Diabetes tester Oculir closes doors, returns capital (VentureWire)
Catalyst Health Ventures raising $60M fund (VentureWire)
Vantia Thera spins out of Ferring, raises £19M – Vantia Therapeutics, a U.K. spinout of Ferring… Continue Reading
Life sciences briefing: Monday, Nov. 12, 2007
(UPDATED: See below.)
Featured companies: Anaptys Biosciences, Arterial Remodeling Technologies, Cambria Biosciences, CaseNet, ChemoCentryx, Ensemble Discovery, MediQuest, Piedmont Pharmaceuticals, Raven Biotechnologies, Sensys Medical, Verus Pharmaceuticals, Xanodyne Pharmaceuticals
UPDATED: Expanded items on Anaptys, Arterial Remodeling, Raven Biotech, Sensys and MediQuest. Moved ChemoCentryx and Xanodyne to a separate item.
Antibody-drug maker Raven Biotech… Continue Reading
Double vision: Ophthotech, Eyetech and Lux BioSciences
When news that the brand-new startup Ophthotech had raised a $36 million first round broke on Monday, it was clear that the venture amounted to a kind of do-over for officials of the late, unlamented Eyetech Pharmaceuticals. Eyetech, you might recall, burst onto the scene… Continue Reading
Life sciences briefing: Monday, Aug. 13, 2007
(UPDATED: See below.)
Featured companies: FoldRx Pharmaceuticals, Ophthotech, Pevion Biotech, Restoration Robotics, Glide Pharma, Reliant Pharmaceuticals, Nanosphere, SurModics, BioFX Laboratories
FoldRx Pharma to receive $22M against cystic fibrosis — Cambridge, Mass.-based FoldRx Pharmaceuticals, a biotech focused on diseases that result from misfolded proteins, will get $22 million over the… Continue Reading
Reata Pharma draws $25M for cancer and inflammation drugs
Irving, Texas-based Reata Pharmaceuticals, a biotech working on new drugs to treat cancer and inflammation, raised $25 million in a fifth funding round. The round was led by existing investors, including CPMG and Novo A/S.
Logical Therapeutics raises $30M, relocates to Boston area
Pittsburgh-based Logical Therapeutics, a developer of drugs for inflammation and metabolic disease, raised $30 million in a second funding round and announced it is moving its headquarters to a location “near Boston.” (What are the odds that the new location might be Cambridge, the hub… Continue Reading